Skip to main content

Cormorant Asset Management — Portfolio, Page 5

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

205
Companies
$24.7B
Total invested
$149.5M
Avg. check
16
Industries
Biotechnology 22Health Care 16Medical 14Therapeutics 10Pharmaceutical 9Oncology 5+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 97120 of 205
Harpoon Therapeutics
October 2023

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.

Biotechnology · South San Francisco$100.0M Post-IPO Equity
Electra Therapeutics
October 2025

Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunological diseases and cancer.

Biotechnology · San Francisco$183.0M Series C
Orionis Biosciences
October 2022

Orionis Biosciences operates in the healthcare industry focusing on biotechnology business & innovation.

Biotechnology · Waltham$55.0M Series C
Tricida
October 2022

Tricida operates in the healthcare industry focusing on pharmaceutical business.

Health Care · Menlo Park$125.0M Post-IPO Debt
C4 Therapeutics
October 2025

C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.

Biotechnology · Cambridge$125.0M Post-IPO Equity
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post Ipo Equity
Candid Therapeutics
March 2026

Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.

Biotechnology · San Diego$505.0M Undisclosed
Beam Therapeutics
February 2026

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Biotechnology · Cambridge$100.0M Post Ipo Debt
Third Arc Bio
February 2026

Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.

Biotechnology · Boston$52.0M Series A
Adlai Nortye
February 2026

Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer treatments for diverse tumor types.

Biotechnology · Hangzhou$140.0M Post Ipo Equity
Monte Rosa Therapeutics
January 2026

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.

Biotechnology · Basel$300.0M Post Ipo Equity
Parabilis Medicines
January 2026

Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.

Biopharma · Cambridge$305.0M Series F
Alumis
January 2026

Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

Biotechnology · San Francisco$345.1M Post Ipo Equity
Praxis Precision Medicines
January 2026

Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.

Alternative Medicine · Cambridge$575.0M Post Ipo Equity
BlossomHill Therapeutics
December 2025

BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.

Biopharma · San Diego$84.0M Series B
Wave Life Sciences
December 2025

Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases

Biotechnology · Boston$350.0M Post Ipo Equity
Structure Therapeutics
December 2025

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

Biotechnology · South San Francisco$747.5M Post Ipo Equity
Akura Medical
December 2025

Akura Medical is developing a next-generation thrombectomy device that aims to simplify thrombectomy through an easy-to-use.

Health Care · Los Gatos$53.0M Series C
Tessera Therapeutics
December 2025

Tessera Therapeutics is a biotechnology company pioneering Gene Writing™ to drive advancements in genome engineering.

Biopharma · Cambridge$150.0M Corporate Round
Aspen Neuroscience
November 2025

Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies and autologous regenerative medicine.

Biotechnology · San Diego$115.0M Series C
Freenome
November 2025

Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.

Biotechnology · South San Francisco$75.0M Corporate Round
Centessa Pharmaceuticals
November 2025

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process.

Biotechnology · Cambridge$250.0M Post Ipo Equity
MoonLake Immunotherapeutics
November 2025

MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.

Biotechnology · Zug$75.0M Post Ipo Equity
X4 Pharmaceuticals
October 2025

X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.

Biotechnology · Cambridge$155.3M Post Ipo Equity

Where Cormorant Asset Management invests

Biotechnology22
Health Care16
Medical14
Therapeutics10
Pharmaceutical9
Oncology5

About Cormorant Asset Management's portfolio

How many companies has Cormorant Asset Management invested in?

Cormorant Asset Management has invested in 205 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Cormorant Asset Management invest in?

Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 16 different industry categories.

What is Cormorant Asset Management's largest investment?

Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post Ipo Equity round. Cormorant Asset Management's total known invested capital is $24.7B.

What is the average investment size for Cormorant Asset Management?

Cormorant Asset Management's average investment size is $149.5M across its portfolio of 205 companies.

What are Cormorant Asset Management's most recent investments?

Recent Cormorant Asset Management portfolio additions include Harpoon Therapeutics, Electra Therapeutics, Orionis Biosciences, Tricida, C4 Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 205 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →